Bristol-Myers Squibb (BMS) and bluebird bio announced that the Food and Drug Administration (FDA) has approved the marketing of Abecma (idecabtagene vicleucel), a chimeric antigen receptor T (CAR-T) cell immunotherapy targeting BRead More…
Science Translational Medicine: New Costimulatory Signal Enables CAR-T to Show Potential of Treating Solid Tumor
T cells expressing chimeric antigen receptors (CAR-T) are one of the major breakthroughs in the field of cancer treatment in recent years, and they have achieved excellent efficacy in the treatment ofRead More…
TOP 10 Research Advances in 2020 on CAR-T Cells
In recent years, CAR-T cells have shown great potential in experimental research and clinical treatment of various malignant tumors since they are of high specificity and strong anti-tumor immune function, especially inRead More…
CAR-T Therapy Evolution—Application of Non-viral Vector and Gene Knock-in Technology
As a precision targeted therapy for tumor treatment, CAR-T (chimeric antigen receptor t-cell immunotherapy) has achieved promising results in clinical tumor treatment with optimization and improvement in recent years. It is cutting-edgeRead More…
The Potential of CAR-Macrophages Therapy in Novel Coronavirus Clearance
At present, the vaccine research for the Coronavirus Disease (COVID-19) is in progress, but the drug research and development for severe COVID-19 remains a thorny scientific problem. Up to now, there isRead More…
FDA Approves the First IND Application for Universal CAR-T Therapy Derived from iPSC
On July 9th, Fate Therapeutics announced that U.S. Food and Drug Administration has approved the first IND application for iPSC-derived allogeneic CAR-T cell therapy FT819 for the treatment of recurrent/refractory B-cell malignant tumors,Read More…
HLA System and HLA Typing
The human leukocyte antigen (HLA) system or complex is a group of highly polymorphic genomes on chromosomes that encode major histocompatibility complex (MHC) proteins which are expressed on the surface of cellRead More…
PNAS: Targeting Tox and Tox2 is Expected to Improve the Treatment of Solid Tumors by CAR-T Cell Immunotherapy.
Ten years ago, scientists announced the development of cancer immunotherapy called chimeric antigen receptor-T cell (CAR-T) therapy: genetically modifying T cells from patients to make them powerful anti-tumor effects, and then infusingRead More…
For the first time! Production of CAR-T cells expressing anti-CD19 without virus and plasmid
Recently, it was announced that LineaRx (a part of Applied DNA Science), a company specializing in next-generation biotherapy, has achieved anti-CD19-CAR (chimeric antigen receptor) expression on human T cells through its proprietaryRead More…
Scientists Found a Novel Strategy to Resist T Cell Failure In CAR-T Cell Therapy
More and more cancer patients are receiving a promising new treatment called CAR-T cell therapy. In this treatment, the patient’s own T cells are removed from the body and genetically modified toRead More…